Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Dualta McQuaid is active.

Publication


Featured researches published by Dualta McQuaid.


Radiotherapy and Oncology | 2012

Dosimetric explanations of fatigue in head and neck radiotherapy: An analysis from the PARSPORT Phase III trial

S. Gulliford; Aisha Miah; Sinead Brennan; Dualta McQuaid; Catharine H. Clark; Mike Partridge; Kevin J. Harrington; James Morden; Emma Hall; Christopher M. Nutting

BACKGROUND An unexpected finding from the phase III parotid sparing radiotherapy trial, PARSPORT (ISRCTN48243537, CRUK/03/005), was a statistically significant increase in acute fatigue for those patients who were treated with intensity-modulated radiotherapy (IMRT) compared to standard conventional radiotherapy (CRT). One possible explanation was the difference in dose to central nervous system (CNS) structures due to differing beam portals. Using data from the trial, a dosimetric analysis of individual CNS structures was performed. METHOD Dosimetric and toxicity data were available for 67 patients (27 CRT, 40 IMRT). Retrospective delineation of the posterior fossa, brainstem, cerebellum, pituitary gland, pineal gland, hypothalamus, hippocampus and basal ganglia was performed. Dosimetry was reviewed using summary statistics and dose-volume atlases. RESULTS A statistically significant increase in maximum and mean doses to each structure was observed for patients who received IMRT compared to those who received CRT. Both maximum and mean doses were significantly higher for the posterior fossa, brainstem and cerebellum for the 42 patients who reported acute fatigue of Grade 2 or higher (p ≤ 0.01) compared to the 25 who did not. Dose-volume atlases of the same structures indicated that regions representing larger volumes and higher doses to each structure were consistent with a higher incidence of acute fatigue. There was no association between the dose distribution and acute fatigue for the other structures tested. CONCLUSIONS The excess fatigue reported in the IMRT arm of the trial may, at least in part, be attributed to the dose distribution to the posterior fossa, cerebellum and brainstem. Future studies that modify dose delivery to these structures may allow us to test the hypothesis that radiation-induced fatigue is avoidable.


Clinical Oncology | 2014

Neurocognitive Function After (Chemo)-Radiotherapy for Head and Neck Cancer

Liam Welsh; Alex Dunlop; T. McGovern; Dualta McQuaid; Jamie A. Dean; S. Gulliford; Shreerang A. Bhide; Kevin J. Harrington; Christopher M. Nutting; K. Newbold

Radical radiotherapy has a pivotal role in the treatment of head and neck cancer (HNC) and cures a significant proportion of patients while simultaneously sparing critical normal organs. Some patients treated with radical radiotherapy for HNC receive significant radiation doses to large volumes of brain tissue. In fact, intensity-modulated radiotherapy techniques for HNC have been associated with a net increase in irradiated brain volumes. The increasing use of chemoradiotherapy for HNC has additionally exposed this patient population to potential neurotoxicity due to cytotoxic drugs. Patients with HNC may be particularly at risk for adverse late brain effects after (chemo)-radiotherapy, such as impaired neurocognitive function (NCF), as risk factors for the development of HNC, such as smoking, excess alcohol consumption and poor diet, are also associated with impaired NCF. The relatively good survival rates with modern treatment for HNC, and exposure to multiple potentially neurotoxic factors, means that it is important to understand the impact of (chemo)-radiotherapy for HNC on NCF, and to consider what measures can be taken to minimise treatment-related neurotoxicity. Here, we review evidence relating to the late neurotoxicity of radical (chemo)-radiotherapy for HNC, with a focus on studies of NCF in this patient population.


The Journal of Nuclear Medicine | 2016

The predictive value of early assessment after one cycle of induction chemotherapy with 18F-FDG-PET/CT and DW-MRI for response to radical chemoradiotherapy in head and neck squamous cell carcinoma

Kee Howe Wong; Rafal Panek; Liam Welsh; Dualta McQuaid; Alex Dunlop; Angela M. Riddell; Iain Murray; Sue Chua; Dow-Mu Koh; Shreerang A. Bhide; Christopher M. Nutting; Wim J.G. Oyen; Kevin J. Harrington; Kate Newbold

The objective of this study was to assess the predictive value of early assessment (after 1 cycle of induction chemotherapy [IC]) with 18F-FDG PET/CT and diffusion-weighted (DW) MRI for subsequent response to radical chemoradiotherapy in locally advanced head and neck squamous cell carcinoma (HNSCC). Methods: Twenty patients with stage III–IVa HNSCC prospectively underwent 18F-FDG PET/CT and DW MRI before and 2 wk after each cycle of IC (first cycle, IC1; second cycle, IC2). Response was assessed 3 mo after completion of chemoradiotherapy with clinical examination, MRI, and 18F-FDG PET/CT. Patients with persistent disease were classed as nonresponders. Changes in functional and molecular imaging parameters after IC1 were compared between responders and nonresponders with the Mann–Whitney U test. The significance threshold was set at a P value of less than 0.05. Results: Responders showed a significantly greater reduction in metabolic tumor volume (P = 0.03) and total lesion glycolysis (P = 0.04) after IC1 than nonresponders. Responders also showed a tendency toward a larger but statistically nonsignificant increase in apparent diffusion coefficient after IC1. There was no significant difference in the changes from baseline between the IC1 and IC2 for all functional and molecular imaging parameters, indicating that most biologic response to IC measured by 18F-FDG PET/CT and DW MRI was observed early after the first cycle of IC. Conclusion: Our preliminary data indicate that the 18F-FDG PET/CT–derived metabolic tumor volume or total lesion glycolysis, acquired after IC1, are early predictive biomarkers for ultimate response to subsequent chemoradiotherapy. These early biomarkers enable identification of patients at risk of treatment failure at an early time point, permitting treatment individualization and consideration of alternative strategies such as radiotherapy dose escalation or surgery.


Journal of Magnetic Resonance Imaging | 2016

Repeatability and sensitivity of T2* measurements in patients with head and neck squamous cell carcinoma at 3T

Rafal Panek; Liam Welsh; Alex Dunlop; Kee H. Wong; Angela M. Riddell; Dow-Mu Koh; Maria A. Schmidt; Simon J. Doran; Dualta McQuaid; Georgina Hopkinson; Cheryl Richardson; Christopher M. Nutting; Shreerang A. Bhide; Kevin J. Harrington; Simon P. Robinson; Kate Newbold; Martin O. Leach

To determine whether quantitation of T2* is sufficiently repeatable and sensitive to detect clinically relevant oxygenation levels in head and neck squamous cell carcinoma (HNSCC) at 3T.


Radiotherapy and Oncology | 2016

Assessment of fully-automated atlas-based segmentation of novel oral mucosal surface organ-at-risk

Jamie A. Dean; Liam Welsh; Dualta McQuaid; Kee H. Wong; Aleksandar Aleksic; Emma Dunne; Mohammad R. Islam; Anushka Patel; Priyanka Patel; Imran Petkar; Iain Phillips; Jackie Sham; Kate Newbold; Shreerang A. Bhide; Kevin J. Harrington; S. Gulliford; Christopher M. Nutting

BACKGROUND AND PURPOSE Current oral mucositis normal tissue complication probability models, based on the dose distribution to the oral cavity volume, have suboptimal predictive power. Improving the delineation of the oral mucosa is likely to improve these models, but is resource intensive. We developed and evaluated fully-automated atlas-based segmentation (ABS) of a novel delineation technique for the oral mucosal surfaces. MATERIAL AND METHODS An atlas of mucosal surface contours (MSC) consisting of 46 patients was developed. It was applied to an independent test cohort of 10 patients for whom manual segmentation of MSC structures, by three different clinicians, and conventional outlining of oral cavity contours (OCC), by an additional clinician, were also performed. Geometric comparisons were made using the dice similarity coefficient (DSC), validation index (VI) and Hausdorff distance (HD). Dosimetric comparisons were carried out using dose-volume histograms. RESULTS The median difference, in the DSC and HD, between automated-manual comparisons and manual-manual comparisons were small and non-significant (-0.024; p=0.33 and -0.5; p=0.88, respectively). The median VI was 0.086. The maximum normalised volume difference between automated and manual MSC structures across all of the dose levels, averaged over the test cohort, was 8%. This difference reached approximately 28% when comparing automated MSC and OCC structures. CONCLUSIONS Fully-automated ABS of MSC is suitable for use in radiotherapy dose-response modelling.


PLOS ONE | 2015

Brain-Sparing Methods for IMRT of Head and Neck Cancer

Alex Dunlop; Liam Welsh; Dualta McQuaid; Jamie A. Dean; S. Gulliford; Vibeke N. Hansen; Shreerang A. Bhide; Christopher M. Nutting; Kevin J. Harrington; Kate Newbold

Purpose Radical radiotherapy for head and neck cancer (HNC) may deliver significant doses to brain structures. There is evidence that this may cause a decline in neurocognitive function (NCF). Radiation dose to the medial temporal lobes, and particularly to the hippocampi, seems to be critical in determining NCF outcomes. We evaluated the feasibility of two alternative intensity-modulated radiotherapy (IMRT) techniques to generate hippocampus- and brain-sparing HNC treatment plans to preserve NCF. Methods and Materials A planning study was undertaken for ten patients with HNC whose planning target volume (PTV) included the nasopharynx. Patients had been previously treated using standard (chemo)-IMRT techniques. Bilateral hippocampi were delineated according to the RTOG atlas, on T1w MRI co-registered to the RT planning CT. Hippocampus-sparing plans (HSRT), and whole-brain/hippocampus-sparing fixed-field non-coplanar IMRT (BSRT) plans, were generated. DVHs and dose difference maps were used to compare plans. NTCP calculations for NCF impairment, based on hippocampal dosimetry, were performed for all plans. Results Significant reductions in hippocampal doses relative to standard plans were achieved in eight of ten cases for both HSRT and BSRT. EQD2 D40% to bilateral hippocampi was significantly reduced from a mean of 23.5 Gy (range 14.5–35.0) in the standard plans to a mean of 8.6 Gy (4.2–24.7) for HSRT (p = 0.001) and a mean of 9.0 Gy (4.3–17.3) for BSRT (p < 0.001). Both HSRT and BSRT resulted in a significant reduction in doses to the whole brain, brain stem, and cerebellum. Conclusion We demonstrate that IMRT plans for HNC involving the nasopharynx can be successfully optimised to significantly reduce dose to the bilateral hippocampi and whole brain. The magnitude of the achievable dose reductions results in significant reductions in the probability of radiation-induced NCF decline. These results could readily be translated into a future clinical trial.


Journal of Applied Clinical Medical Physics | 2017

Lung volume reproducibility under ABC control and self‐sustained breath‐holding

Evangelia Kaza; Alex Dunlop; Rafal Panek; David J. Collins; Matthew R. Orton; Richard Symonds-Tayler; Dualta McQuaid; Erica Scurr; Vibeke N. Hansen; Martin O. Leach

&NA; An Active Breathing Coordinator (ABC) can be employed to induce breath‐holds during CT imaging and radiotherapy of lung, breast and liver cancer, and recently during lung cancer MRI. The apparatus measures and controls respiratory volume, hence subject lung volume reproducibility is its principal measure of effectiveness. To assess ABC control quality, the intra‐session reproducibility of ABC‐induced lung volumes was evaluated and compared with that reached by applying the clinical standard of operator‐guided self‐sustained breath‐holds on healthy volunteers during MRI. Inter‐session reproducibility was investigated by repeating ABC‐controlled breath‐holds on a second visit. Additionally, lung volume agreement with ABC devices used with different imaging modalities in the same institution (MR, CT), or for a breast trial treatment, was assessed. Lung volumes were derived from three‐dimensional (3D) T1‐weighted MRI datasets by three observers employing semiautomatic lung delineation on a radiotherapy treatment planning system. Inter‐observer variability was less than 6% of the delineated lung volumes. Lung volume agreement between the different conditions over all subjects was investigated using descriptive statistics. The ABC equipment dedicated for MR application exhibited good intra‐session and inter‐session lung volume reproducibility (1.8% and 3% lung volume variability on average, respectively). MR‐assessed lung volumes were similar using different ABC equipment dedicated to MR, CT, or breast radiotherapy. Overall, lung volumes controlled by the same or different ABC devices agreed better than with self‐controlled breath‐holds, as suggested by the average ABC variation of 1.8% of the measured lung volumes (99 mL), compared to the 4.1% (226 mL) variability observed on average with self‐sustained breath‐holding.


Clinical Cancer Research | 2017

Noninvasive Imaging of Cycling Hypoxia in Head and Neck Cancer Using Intrinsic Susceptibility MRI

Rafal Panek; Liam Welsh; Lauren C.J. Baker; Maria A. Schmidt; Kee H. Wong; Angela M. Riddell; Dow-Mu Koh; Alex Dunlop; Dualta McQuaid; James A. d'Arcy; Shreerang A. Bhide; Kevin J. Harrington; Christopher M. Nutting; Georgina Hopkinson; Cheryl Richardson; Carol Box; Suzanne A. Eccles; Martin O. Leach; Simon P. Robinson; Kate Newbold

Purpose: To evaluate intrinsic susceptibility (IS) MRI for the identification of cycling hypoxia, and the assessment of its extent and spatial distribution, in head and neck squamous cell carcinoma (HNSCC) xenografts and patients. Experimental Design: Quantitation of the transverse relaxation rate, R2*, which is sensitive to paramagnetic deoxyhemoglobin, using serial IS-MRI acquisitions, was used to monitor temporal oscillations in levels of paramagnetic deoxyhemoglobin in human CALR xenografts and patients with HNSCC at 3T. Autocovariance and power spectrum analysis of variations in R2* was performed for each imaged voxel, to assess statistical significance and frequencies of cycling changes in tumor blood oxygenation. Pathologic correlates with tumor perfusion (Hoechst 33342), hypoxia (pimonidazole), and vascular density (CD31) were sought in the xenografts, and dynamic contrast-enhanced (DCE) MRI was used to assess patient tumor vascularization. The prevalence of fluctuations within patient tumors, DCE parameters, and treatment outcome were reported. Results: Spontaneous R2* fluctuations with a median periodicity of 15 minutes were detected in both xenografts and patient tumors. Spatially, these fluctuations were predominantly associated with regions of heterogeneous perfusion and hypoxia in the CALR xenografts. In patients, R2* fluctuations spatially correlated with regions of lymph nodes with low Ktrans values, typically in the vicinity of necrotic cores. Conclusions: IS-MRI can be used to monitor variations in levels of paramagnetic deoxyhemoglobin, associated with cycling hypoxia. The presence of such fluctuations may be linked with impaired tumor vasculature, the presence of which may impact treatment outcome. Clin Cancer Res; 23(15); 4233–41. ©2017 AACR.


European Journal of Nuclear Medicine and Molecular Imaging | 2018

Changes in multimodality functional imaging parameters early during chemoradiation predict treatment response in patients with locally advanced head and neck cancer

Kee H. Wong; Rafal Panek; Alex Dunlop; Dualta McQuaid; Angela M. Riddell; Liam Welsh; Iain Murray; Dow-Mu Koh; Martin O. Leach; Shreerang A. Bhide; Christopher M. Nutting; Wim J.G. Oyen; Kevin J. Harrington; Kate Newbold

ObjectiveTo assess the optimal timing and predictive value of early intra-treatment changes in multimodality functional and molecular imaging (FMI) parameters as biomarkers for clinical remission in patients receiving chemoradiation for head and neck squamous cell carcinoma (HNSCC).MethodsThirty-five patients with stage III-IVb (AJCC 7th edition) HNSCC prospectively underwent 18F–FDG-PET/CT, and diffusion-weighted (DW), dynamic contrast-enhanced (DCE) and susceptibility-weighted MRI at baseline, week 1 and week 2 of chemoradiation. Patients with evidence of persistent or recurrent disease during follow-up were classed as non-responders. Changes in FMI parameters at week 1 and week 2 were compared between responders and non-responders with the Mann–Whitney U test. The significance threshold was set at a p value of <0.05.ResultsThere were 27 responders and 8 non-responders. Responders showed a greater reduction in PET-derived tumor total lesion glycolysis (TLG40%; p = 0.007) and maximum standardized uptake value (SUVmax; p = 0.034) after week 1 than non-responders but these differences were absent by week 2. In contrast, it was not until week 2 that MRI-derived parameters were able to discriminate between the two groups: larger fractional increases in primary tumor apparent diffusion coefficient (ADC; p < 0.001), volume transfer constant (Ktrans; p = 0.012) and interstitial space volume fraction (Ve; p = 0.047) were observed in responders versus non-responders. ADC was the most powerful predictor (∆ >17%, AUC 0.937).ConclusionEarly intra-treatment changes in FDG-PET, DW and DCE MRI-derived parameters are predictive of ultimate response to chemoradiation in HNSCC. However, the optimal timing for assessment with FDG-PET parameters (week 1) differed from MRI parameters (week 2). This highlighted the importance of scanning time points for the design of FMI risk-stratified interventional studies.


International Journal of Radiation Oncology Biology Physics | 2018

MRI-based Assessment of 3D Intrafractional Motion of Head and Neck Cancer for Radiation Therapy

Oliver J. Gurney-Champion; Dualta McQuaid; Alex Dunlop; Kee H. Wong; Liam Welsh; Angela M. Riddell; Dow-Mu Koh; Uwe Oelfke; Martin O. Leach; Christopher M. Nutting; Shreerang A. Bhide; Kevin J. Harrington; Rafal Panek; Kate Newbold

Purpose To determine the 3-dimensional (3D) intrafractional motion of head and neck squamous cell carcinoma (HNSCC). Methods and Materials Dynamic contrast-enhanced magnetic resonance images from 56 patients with HNSCC in the treatment position were analyzed. Dynamic contrast-enhanced magnetic resonance imaging consisted of 3D images acquired every 2.9 seconds for 4 minutes 50 seconds. Intrafractional tumor motion was studied in the 3 minutes 43 seconds of images obtained after initial contrast enhancement. To assess tumor motion, rigid registration (translations only) was performed using a region of interest (ROI) mask around the tumor. The results were compared with bulk body motion from registration to all voxels. Motion was split into systematic motion and random motion. Correlations between the tumor site and random motion were tested. The within-subject coefficient of variation was determined from 8 patients with repeated baseline measures. Random motion was also assessed at the end of the first week (38 patients) and second week (25 patients) of radiation therapy to investigate trends of motion. Results Tumors showed irregular occasional rapid motion (eg, swallowing or coughing), periodic intermediate motion (respiration), and slower systematic drifts throughout treatment. For 95% of the patients, displacements due to systematic and random motion were <1.4 mm and <2.1 mm, respectively, 95% of the time. The motion without an ROI mask was significantly (P<.0001, Wilcoxon signed rank test) less than the motion with an ROI mask, indicating that tumors can move independently from the bony anatomy. Tumor motion was significantly (P=.005, Mann-Whitney U test) larger in the hypopharynx and larynx than in the oropharynx. The within-subject coefficient of variation for random motion was 0.33. The average random tumor motion did not increase notably during the first 2 weeks of treatment. Conclusions The 3D intrafractional tumor motion of HNSCC is small, with systematic motion <1.4 mm and random motion <2.1 mm 95% of the time.

Collaboration


Dive into the Dualta McQuaid's collaboration.

Top Co-Authors

Avatar

Alex Dunlop

The Royal Marsden NHS Foundation Trust

View shared research outputs
Top Co-Authors

Avatar

Christopher M. Nutting

The Royal Marsden NHS Foundation Trust

View shared research outputs
Top Co-Authors

Avatar

Kevin J. Harrington

Institute of Cancer Research

View shared research outputs
Top Co-Authors

Avatar

Shreerang A. Bhide

The Royal Marsden NHS Foundation Trust

View shared research outputs
Top Co-Authors

Avatar

Liam Welsh

The Royal Marsden NHS Foundation Trust

View shared research outputs
Top Co-Authors

Avatar

Angela M. Riddell

The Royal Marsden NHS Foundation Trust

View shared research outputs
Top Co-Authors

Avatar

K. Newbold

The Royal Marsden NHS Foundation Trust

View shared research outputs
Top Co-Authors

Avatar

Kate Newbold

The Royal Marsden NHS Foundation Trust

View shared research outputs
Top Co-Authors

Avatar

Rafal Panek

The Royal Marsden NHS Foundation Trust

View shared research outputs
Top Co-Authors

Avatar

Dow-Mu Koh

Institute of Cancer Research

View shared research outputs
Researchain Logo
Decentralizing Knowledge